The regular meetings of Beacon Angels in 2023 covered the following:

July 11, 2023

Palla.ai & CranioSense

At the Beacon Angels meeting on Tuesday, July 11, 2023, members heard funding proposals from the following candidates:

• 8:30 – 9:00 AM, Palla.ai, using AI and technology, to develop sabremetric analytical tools for soccer teams; and
• 9:15 – 9:45 AM CranioSense, developing a medical device to rapidly assess intracranial pressure state to minimize time-to-treatment.

Members reported on pending funding rounds, by Series number.

• 108 AOA Dx, raised $15 MM Series A at $25 MM pre-money—invested $256K; closed as of July 10th.
• 113 RevBio—$3 MM convertible debt, $90 MM cap invested 28K; closed.
• 114 NeoSoma, offering an AI-enabled SAAS platform for brain tumor analysis and clinical management to physician teams and drug developers; and
• 115 ClearLaw, offering natural language processing models for corporate legal departments to analyze contracts and extract data.

Members to report on the companies now in due diligence:

• Conversifi, which assists language learners, who collectively spend $90B a year, to learn to speak another language, by providing on-demand immersive live chat with native speakers. (awaiting response from Steven Kruubiner).
• NED Medical, developing CombiSphere to co-administer chemoradiotherapy at liver tumor sites and thus lower side effects and improve outcomes;
• RBI Medical (Serrao in lead, with Davis, Doscher, Fogel & Richard), developing novel bioelectronic micro-implants to treat urinary incontinence and other pelvic health conditions; and
• RealPlay, offering an AI-driven platform to enable sports facilities and tournament operators to sell video subscriptions to players, parents, fans, coaches and scouts.

September 12, 2023

EmTech & myBiometry

At its meeting on Tuesday, September 12, 2023, entertained new funding proposals from the following:

• Emitech (Marina Kateyeva), developing device “OpiTest”, a rapid, non-invasive, on-site, accurate detection of narcotics in the human body and in fentanyl-laced fake medications; and
• myBiometry (Bryan Nolan), developing a solution for the early detection of asthma attacks up to 20 days in advance using intelligent diagnostics + connected monitoring.

We heard follow-on funding presentations as follows:

• RT Microfluidics (Nathalya Mamane), developing a platform for saliva-based at-home diagnostics using molecular technologies.
• Dermal Photonics. CEO David Bean reported on Dermal’s successful rollout of its version 2 device..

Members reported on the many pending funding rounds, by Series number:

• 114 NeoSoma convertible debt round (completed);
• 115 ClearLaw, offering natural language processing models for corporate legal departments to analyze contracts and extract data (in progress–awaiting update)(completed);
• 116 RealPlay priced round (completed);
• 117 RBI Medical, developing novel bioelectronic micro-implants to treat urinary incontinence and other pelvic health conditions (completed);
• 118 Lenoss Medical, convertible debt extension developing a system to inject new bone into collapsed vertebra, extension round (completed);
• 119 Dermal Photonics Series A round, expanding its line of skin-smoothing devices; and
• 120 Spiro Technologies extension round (completed).

Members reported on companies in due diligence: 

• Conversifi, assisting language learners, who collectively spend $90B a year, to learn to speak another language, by providing on-demand immersive live chat with native speakers.
• NED Medical, developing CombiSphere to co-administer chemoradiotherapy at liver tumor sites and thus lower side effects and improve outcomes;
• RBI Medical–see above.

October12, 2023

Zelegent & RealNose

At its meeting on Tuesday, October12, 2023, Beacon Angels members entertained new funding proposals from the following:

• Zelegent (David Elliot) has developed and launched an FDA-cleared Elevo® Snoring Intervention Set for doctors to treat patients in their offices with Elevoplasty® for mild to moderate snoring.
• RealNose (Nikolas Stefanou) offers AI-trained, bio programmable olfactory sensors that map scent profiles, initially to help doctors detect prostate cancer in patients.

We heard a follow-on funding presentation:

• QSM Medical sells diagnostic mail-in kits and instruments to veterinarians. These kits and instruments enable pet owners to obtain diagnostic testing results faster.

Members reported on companies now in due diligence: 

• Conversifi, which assists language learners, who collectively spend $90B a year, to learn to speak another language, by providing on-demand immersive live chat with native speakers.
• NED Medical, developing CombiSphere to co-administer chemoradiotherapy at liver tumor sites and thus lower side effects and improve outcomes; and
• myBiometry, offering early warning of asthma attacks up to 20 days in advance using intelligent diagnostics and connected monitoring. They are closing out a round that includes Launchpad Ventures and Cherrystone.